All Articles

This edition of Year in Review is focused on gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) cancer, and immunotherapy and targeted therapies used in the management of these cancers.

Results from the KEYNOTE-811 clinical trial indicate pembrolizumab added to trastuzumab plus chemotherapy improves response in HER2-positive gastric or gastroesophageal junction cancer.

Andecaliximab plus modified (m)FOLFOX6 first-line therapy for metastatic gastric adenocarcinoma did not improve study outcomes in an unselected study population, but improved efficacy was reported in patients ≥65 years of age.

Results from a single-arm phase 2 study show ramucirumab plus irinotecan yields promising antitumor activity and safety results in patients with advanced gastric cancer.

The addition of neoadjuvant chemotherapy to D2 surgery plus adjuvant chemotherapy improves progression-free survival in patients with resectable locally advanced gastric cancer.

Clinical study results indicate pembrolizumab monotherapy improves response rate in patients with advanced refractory esophageal cancer.

Avelumab maintenance therapy conveys no overall survival difference over the use of continued chemotherapy in patients with advanced GEJC or gastric cancer.

The dose-escalation phase of the EMERGE clinical trial results show that 200 mg domatinostat twice daily is safe and efficacious.

No survival advantage was observed with durvalumab use in the PLATFORM clinical trial, but a patient subgroup was observed to have a radiological response.

CheckMate-577 clinical trial results show nivolumab adjuvant therapy increases disease-free survival over placebo in patients with gastroesophageal junction (GEJ) cancer or esophageal cancer.